In addition, humanized mice subcutaneously transplanted with KG1 could significantly inhibit the growth of tumors by oral administration of pemigatinib, and phase II clinical trials have been carried out in FGFR1 rearranged myeloid/lymphoid tumors (FIGHT, NCT03011372) (121). The gene discussed is FGFR1; the disease is lymphoid neoplasm.